Please login to the form below

Not currently logged in
Email:
Password:

Linda Law joins Advicenne as US VP, clinical development and med affairs

She will oversee the biopharma’s developments with its dTRA candidate

Linda Late-stage biopharmaceutical company Advicenne has appointed Linda Law as its new US vice president of clinical development and medical affairs.

Law will take responsibility for the group’s efforts in North America, which are focused on its distal Renal Acidosis (dTRA) candidate and she will report to Advicenne’s chief executive officer Dr Luc-André Granier.

She brings 20 years’ of experience in international pharmaceutical development and medical affairs across a range of therapeutic areas to the group.

Commenting on her appointment, Granier said: “This is a pivotal time for Advicenne and Dr Law’s experience and deep knowledge of US clinical development will be of great value of Advicenne.

“Her appointment also marks the start of the company’s US operations.”

Law’s career has seen her serve in various positions for pharmaceutical companies including Procter & Gamble, Lexicon Pharmaceuticals and she has consulted on evaluation and development projects with Takeda, Confluence and Forest Pharmaceuticals.

1st February 2018

From: Research

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
integrated medhealth communication

imc group is a leading, independent global healthcare communication group that enables client’s brands to connect with healthcare professionals, payers...

Latest intelligence

Market Shaping for Better Healthcare Decisions
82% of healthcare business professionals agreed that it is important to get market shaping right to achieve future brand success....
launch engagement
Launch engagement
How the pandemic is forcing a fresh focus on the human touch and fresh thinking about engagement...
Everything you need to know about patient groups and clinical trials
Patient advocacy groups (PAGs) and pharma/biopharma/biotech and MedTech industries are all working towards the same goal: to improve health outcomes. And as PAGs are key stakeholders in the clinical trial...